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Abstract
Background: Cardiovascular disease is the cause of death in 32% of women in the Netherlands. Prediction of an 
individual's risk for cardiovascular disease is difficult, in particular in younger women due to low sensitive and specific 
tests for these women. 10% to 15% of all pregnancies are complicated by hypertensive disorders, the vast majority of 
which develop only after 36 weeks of gestation. Preeclampsia and cardiovascular disease in later life show both 
features of "the metabolic syndrome" and atherosclerosis. Hypertensive disorders in pregnancy and cardiovascular 
disease may develop by common pathophysiologic pathways initiated by similar vascular risk factors. Vascular damage 
occurring during preeclampsia or gestational hypertension may contribute to the development of future 
cardiovascular disease, or is already present before pregnancy. At present clinicians do not systematically aim at the 
possible cardiovascular consequences in later life after a hypertensive pregnancy disorder at term. However, screening 
for risk factors after preeclampsia or gestational hypertension at term may give insight into an individual's 
cardiovascular risk profile.
Methods/Design: Women with a history of preeclampsia or gestational hypertension will be invited to participate in a 
cohort study 2 1/2 years after delivery. Participants will be screened for established modifiable cardiovascular risk 
indicators. The primary outcome is the 10-year cardiovascular event risk. Secondary outcomes include differences in 
cardiovascular parameters, SNP's in glucose metabolism, and neonatal outcome.
Discussion: This study will provide evidence on the potential health gains of a modifiable cardiovascular risk factor 
screening program for women whose pregnancy was complicated by hypertension or preeclampsia. The calculation of 
individual 10-year cardiovascular event risks will allow identification of those women who will benefit from primary 
prevention by tailored interventions, at a relatively young age.
Trial registration: The HYPITAT trial is registered in the clinical trial register as ISRCTN08132825.
Background
Cardiovascular disease is the cause of death of 32% of
women in the Netherlands [1]. Not all women are at the
same risk of cardiovascular disease. Prediction of risk in
younger women is particularly difficult due to low sensi-
tive and specific tests for these women. Identification of
individual women at higher risk is a challenge. This pro-
posal takes an innovative angle to gain insight in cardio-
vascular morbidity and mortality later in life in women
using pregnancy related hypertensive complications.
Approximately 10% to 15% of all pregnancies are compli-
cated by hypertension and largely contribute to maternal
and neonatal morbidity and mortality worldwide. In the
Netherlands it is the largest single cause of maternal mor-
tality [2]. The vast majority of hypertensive disorders
present themselves after 36 weeks of gestation [3]. There-
fore, we focus in this study on those women with preg-
nancy related hypertensive complications (near) at term
(> 36 weeks gestation).
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not fully understood, but the causal treatment is delivery
of the baby and the placenta. Recently it was shown that
in women at term with gestational hypertension or preec-
lampsia induction of labor is advisable to avoid progres-
sion to more severe disease [4]. However, the health
status of these women after pregnancy has been given lit-
tle of any attention in routine clinical practice up to now.
Obstetricians and midwifes are traditionally completely
focused on pregnancy outcome and do not seem to
bother about the significance of complications of preg-
nancy for the future health of the mother, this is also true
for general practitioners.
Recently, data from epidemiologic studies incited the
novel concept of pregnancy as cardiovascular challenge
test; women who have had a pregnancy complicated by
hypertensive disorders are prone to develop cardiovascu-
lar disease in later life [5-10]. In line with this concept is
that pregnancy acts as a metabolic and cardiovascular
stress test for the mother. During pregnancy a failure to
meet the physiological demands will unmask impaired
organ function, e.g. hypertension will arise and most
often subside after delivery. However, these failures will
remanifest in later life when the cumulative effects of age-
ing diminish the reserves of an already vulnerable (organ)
system [5]. Jonsdottir et al. examined causes of death in
374 women with a history of hypertensive complications
in pregnancy and noted that their death rate from com-
plications of coronary heart disease was significantly
higher than expected from analysis of population data
[11].
This concept is further supported by case-control stud-
ies by others and ourselves, demonstrating that women
with a history of early preeclampsia have higher circulat-
ing concentrations of fasting insulin, lipid and coagula-
tions factors post partum than controls matched for body
mass index [12,13]. These changes in vascular risk mark-
ers in women with a history of preeclampsia are part of
the spectrum of the metabolic syndrome. The metabolic
syndrome is hypothesised to be a key factor underlying
cardiovascular disease and in particular coronary heart
disease.
The mechanism of the link between preeclampsia and
cardiovascular disease has not been clarified. Hyperten-
sive disorders in pregnancy and cardiovascular disease
may develop by common pathophysiologic pathways ini-
tiated by similar risk factors. Permanent vascular damage
may occur during preeclampsia or gestational hyperten-
sion and subsequently contributes to the development of
cardiovascular disease in later life, or cardiovascular dis-
ease is already present before pregnancy. However, deter-
minants or risk indicators to be measured after
pregnancy which would predict cardiovascular disease
are lacking. Such risk indicators may identify women at
risk at an early stage for them to benefit from interven-
tion.
The concept described above is based on studies focus-
ing on early, severe preeclampsia, which is a relatively
rare disorder [14], while preeclampsia at (near) term is
mostly mild and more common (75% of cases) [15].
Therefore, prospective evaluation of those women is
required to identify cardiovascular risk indicators after
hypertensive pregnancy complications at term, with the
eventual aim to offer these women the opportunity for
primary prevention at a relatively young age [16].
We propose a cohort study to establish whether women
with gestational hypertension or preeclampsia at term are
at increased risk for cardiovascular disease in later life,
and if these women are likely to benefit from tailored pre-
ventative interventions directed at modifiable cardiovas-
cular risk indicators at a relative young age.
Methods/Design
Aims
The aim of this study is to identify modifiable risk indica-
tors for future cardiovascular disease 2 1/2 years postpar-
tum in women with (near) term preeclampsia or
gestational hypertension. The proposed research con-
cerns a multi-centre cohort study in women who had a
pregnancy complicated by mild preeclampsia or gesta-
tional hypertension (near) at term which is recently pub-
lished [4]. This study will provide insight on the health
costs and benefits of a screening program for all women
with hypertensive complications at term. This study is
embedded in a Dutch Obstetric Consortium in the Neth-
erlands. Almost all obstetric centres nationwide partici-
pate in this structure, including academic hospitals, non-
academic teaching hospitals and non-teaching hospitals.
Participants: Exposed
In this study women who had preeclampsia or gestational
hypertension at term, who participated in the HYPITAT
study, will be eligible for the follow up study 2 1/2 years
after their delivery. The HYPITAT study was a national
randomised clinical trial in which women 18 years of age
or older with gestational hypertension or mild preec-
lampsia at (near) term were included. Eligible were
women with a singleton pregnancy in cephalic presenta-
tion and a gestational age between 36+0 and 41+0 weeks,
whose pregnancy was complicated by gestational hyper-
tension or mild preeclampsia. Gestational hypertension
was defined as diastolic blood pressure equal to or above
95 mmHg measured at two occasions at least six hours
apart in a woman who was normotensive at the start of
pregnancy until week 20 of gestational age. Mild preec-
lampsia was defined as diastolic blood pressure equal to
or above 90 mmHg measured at two occasions at least six
hours apart combined with proteinuria. Proteinuria was
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tein in a 24 hour urine collection and/or protein/creati-
nine ratio > 30 mg/mmol. Exclusion criteria were severe
gestational hypertension or severe preeclampsia, defined
as diastolic blood pressure ≥ 110 mmHg, systolic blood
pressure ≥ 170 mmHg and/or proteinuria ≥ 5 gram in 24
hours, pre-existing hypertension treated with antihyper-
tensive drugs, diabetes mellitus, diabetes gravidarum
requiring insulin therapy, renal disease, heart disease,
previous caesarean section, HELLP syndrome, oliguria <
500 milliliter in 24 hours, pulmonary edema or cyanosis,
HIV seropositivity, use of intravenous anti-hypertensive
medication, fetal anomalies, intra-uterine growth restric-
tion and abnormalities at the fetal heart rate (FHR) -mon-
itoring. Participants were randomly allocated to
induction of labour or expectant monitoring (n = 1162)
[4].
Women at study entry (randomisation) were inquired
for a follow up 2 years after delivery, the hypertension risk
assessment study (HyRAS).
Participants: Non-exposed
All exposed women will be asked to invite a friend as con-
trol. These women are required to have a history of one
(or multiple) uncomplicated pregnancy (ies). This
method will be used because of expected similar age and
similar potential environmental exposures (i.e. socio-eco-
nomic status). The non-exposed undergo the same proce-
dure as the exposed at the local centre. Relatives of the
exposed or of her partner will not be accepted in the non
exposed group.
If the recruitment of non-exposed subjects in the
method described above is not sufficient, the non-
exposed group will be extended by approaching women
with a history of at least one uncomplicated pregnancy in
midwifery practices from three different locations in the
Netherlands (Groningen, Leiden and The Hague).
Ethical approval
The Hyras and HYPITAT studies were approved both
primarily for all participating hospitals in The Nether-
lands by the medical ethics committee of Leiden Univer-
sity Medical Centre (HYPITAT: P04·210) and locally by
the hospital board of the participating hospitals. The clin-
ical trial registration number of the HYPITAT trial is:
ISRCTN08132825.
Procedures, recruitment and collection of baseline data
Women who participated in the HYPITAT study will be
contacted by the research nurses 2 1/2 years after delivery
(study entry date) and they will be invited to participate
in the HyRAS study in their local centre. Before entry into
the study the research nurse or midwife counsels the
patients, asks informed consent and emphasizes that par-
ticipation is voluntarily. Patients who decide not to par-
ticipate in this study for complete follow up will be asked
to fill out the questionnaire to be analyzed separately.
This questionnaire includes medical history, psychologi-
cal status, social status, use of medication, contraceptive
methods, obstetric history, and family history including
thrombosis, diabetes and cardiovascular disease. Further-
more, pregnancy and lactation are exclusion criteria's for
risk factor screening and those women will be asked to
only fill out the questionnaire and participate for risk fac-
tor screening (blood samples, urine collection and blood
pressure, length, weight and anthropometrics measure-
ment) 3 months after the delivery or lactation, with an
extension to 12 months after the original study entry
date.
After enrollment exposed and non-exposed subjects
will be asked to fill out a questionnaire and will be invited
for risk indicator screening (blood samples, urine collec-
tion and blood pressure, length, weight and anthropo-
metrics measurement). Venous blood samples will be
taken after an overnight fast for analysis of lipids and
lipoproteins, insulin, glucose and high sensitive CRP.
Urine will be collected immediately after waking up for
microalbuminuria. After centrifuging the blood samples
for 9 minutes at 3000 bpm at the local centre, all samples
will be sent to the same laboratory (Medical Centre
Haaglanden, the Hague, the Netherlands) and analyzed
within 24 hours. Plasma will be prepared and stored at -
70°C in 1.5 mL volumes until used. DNA will be isolated
from leukocytes and stored at -20°C. Blood pressure will
be measured manually in sitting position at the right
upper arm. Body height (cm) and -weight (kg) will be
measured with the participant dressed in light under-
clothes wearing shoes (except high heels) and waist cir-
cumference (cm) will be measured on uncovered skin
using an inelastic tape measure with the participant in
upright position, halfway between the rib cage and the
pelvic bone. Hip circumference will also be measured.
Data- collection will be centralized and processed with
adequate precautions to ensure patient confidentially.
With the participant's informed consent, the study results
will be sent to the general practitioner. Participants will
also be informed on the results by mail, and in case of
abnormal results it will be recommended to contact the
general practitioner for evaluation or treatment.
Outcome measures
Primary outcome measure
The primary outcome measure will be the 10-year cardio-
vascular event risk. An absolute 10-year cardiovascular
risk (fatal and non-fatal) of > = 10% as estimated with the
SCORE risk function, will be considered as elevated risk.
In addition, risk will be calculated using the Adult Treat-
ment Panel III risk score, Reynolds Risk Score and
QRISK.
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Secondary outcomes will be differences between exposed
and non-exposed subjects in cardiovascular parameters,
differences in SNP's in glucose metabolism, and neonatal
outcome 2 1/2 years after pregnancy complicated by
preeclampsia and gestational hypertension. Neonatal
outcome includes neurological development and devel-
opment of motor skills at the age of 2 1/2 years. We will
use a parental questionnaire (the Child Behaviour Check-
list (CBCL) and ages and stages questionnaire (ASQ)).
The health costs and benefits of a screening program for




Due to the young age of our participants, the estimated
absolute 10-year cardiovascular risk is likely to be low.
Therefore, the approach taken for each woman is to esti-
mate the risk as if the woman was 60 years of age. This
approach has been recommended in the cardiovascular
risk factor management guidelines for young women with
elevated risk factor levels. We plan to include women in
3:1 ratio, i.e. three women who had hypertension in preg-
nancy as compared to 1 control. A sample size of 414
women (310 exposed, 104 non exposed) is sufficient to
demonstrate a risk increase from 5% to at least 15% (sided
alpha .05. power 80%). This estimate is in line with our
earlier studies showing a risk estimate > = 10% in over
30% of the early preeclampsia women [17].
Data analysis
All data are primarily analyzed to investigate the costs
and potential health benefits of a screening program in
order to assess if this screening programme is justified for
all women with hypertensive pregnancy complications at
term. In order to investigate the association between
hypertensive disorders in pregnancy and maternal car-
diovascular status Mann Whitney U tests or where indi-
cated Chi-square will be used for comparisons between
groups (exposed vs. non-exposed). Analysis in subgroups
(i.e. gestational hypertension and preeclampsia) will be
performed. Logistic regression analyses will be done with
the maternal scores as dependent variables and the meta-
bolic status, obstetric history, cardiovascular risk factors,
diabetes risk factors and as independent variables.
Discussion
Cardiovascular disease is the main cause of death of
women in the Netherlands. In this study we will identify
women that may be at higher risk for cardiovascular dis-
ease by their pregnancy complication: hypertensive preg-
nancy disorders at (near) term. Gestational hypertension
and preeclampsia at (near) term are very common com-
plications in pregnancy. Data concerning long term
effects of pregnancies complicated by a hypertensive dis-
order at (near) term on cardiovascular disease are lacking
for these women. Most studies concerning the effect of
hypertensive disorders in pregnancy and cardiovascular
disease in later life studied women who had severe early-
onset preeclampsia, which is a rare disorder. Therefore,
we conduct present study, which will provide evidence for
the necessity of screening women on cardiovascular risk
factors 2 1/2 years after a pregnancy complicated by term
gestational hypertension or preeclampsia.
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